JP2021534091A5 - - Google Patents

Info

Publication number
JP2021534091A5
JP2021534091A5 JP2021506297A JP2021506297A JP2021534091A5 JP 2021534091 A5 JP2021534091 A5 JP 2021534091A5 JP 2021506297 A JP2021506297 A JP 2021506297A JP 2021506297 A JP2021506297 A JP 2021506297A JP 2021534091 A5 JP2021534091 A5 JP 2021534091A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
carcinoma
cell
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021506297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534091A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/071024 external-priority patent/WO2020030591A1/en
Publication of JP2021534091A publication Critical patent/JP2021534091A/ja
Publication of JP2021534091A5 publication Critical patent/JP2021534091A5/ja
Pending legal-status Critical Current

Links

JP2021506297A 2018-08-05 2019-08-05 抗がん剤の有効性を改善する方法 Pending JP2021534091A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18187408 2018-08-05
EP18187408.2 2018-08-05
PCT/EP2019/071024 WO2020030591A1 (en) 2018-08-05 2019-08-05 Method for improving anticancer agent efficacy

Publications (2)

Publication Number Publication Date
JP2021534091A JP2021534091A (ja) 2021-12-09
JP2021534091A5 true JP2021534091A5 (OSRAM) 2022-06-27

Family

ID=63165228

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506297A Pending JP2021534091A (ja) 2018-08-05 2019-08-05 抗がん剤の有効性を改善する方法

Country Status (11)

Country Link
US (1) US20210299170A1 (OSRAM)
EP (1) EP3829637A1 (OSRAM)
JP (1) JP2021534091A (OSRAM)
KR (1) KR20210040997A (OSRAM)
CN (1) CN112689517A (OSRAM)
AU (1) AU2019317986A1 (OSRAM)
BR (1) BR112021002106A2 (OSRAM)
CA (1) CA3106429A1 (OSRAM)
IL (1) IL280608A (OSRAM)
MX (1) MX2021001394A (OSRAM)
WO (1) WO2020030591A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022170557A1 (en) * 2021-02-10 2022-08-18 Gnt Biotech & Medicals Corporation A pharmaceutical combination and method for overcoming immune suppression or stimulating immune response against cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020064471A (ko) * 2001-02-01 2002-08-09 황성하 소나무숯의 제조방법 및 그의 신규한 항암 치료제로서의용도
CN1657100B (zh) * 2004-02-19 2010-05-05 中国人民解放军军事医学科学院毒物药物研究所 选择性靶向胃癌和淋巴系统的纳米级制剂及其制备方法
WO2006085075A2 (en) * 2005-02-09 2006-08-17 Da Volterra Colonic delivery of active agents
DK1883396T3 (da) 2005-05-18 2013-10-07 Centre Nat Rech Scient Afgivelse af adsorptionsmidler til tyktarmen
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
ES2586135T3 (es) 2010-02-23 2016-10-11 Da Volterra Formulaciones para el suministro oral de adsorbentes en el intestino
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
US10449158B2 (en) 2012-09-21 2019-10-22 Ferring B.V. Pharmaceutical activated carbon composition
EP2876167A1 (en) * 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
JP6685925B2 (ja) 2014-04-17 2020-04-22 シンセティック バイオロジクス，インコーポレイテッド 治療用として改善された特性を有するβ−ラクタマーゼ
FR3027307B1 (fr) 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
JP7113619B2 (ja) * 2014-12-09 2022-08-05 イプセン バイオファーム リミティド リポソーマルイリノテカンによる乳がんの治療
WO2016196605A1 (en) * 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
US10925852B2 (en) * 2015-06-30 2021-02-23 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof

Similar Documents

Publication Publication Date Title
CN103282037B (zh) 抗肿瘤生物碱的联合治疗
Boyiadzis et al. Approved monoclonal antibodies for cancer therapy
US20160287717A1 (en) Core and Surface Modification of Mesoporous Silica Nanoparticles to Achieve Cell Specific Targeting In Vivo.
KR20200067164A (ko) 조합 요법 및 그의 용도
RU2019109211A (ru) Композиции, содержащие носитель-pd-l1-связывающий агент для лечения рака
US11034757B2 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
CN109196103A (zh) 自组装的3d rna笼形纳米粒
KR102433719B1 (ko) 약물 로딩된, 이중특이성 리간드-표적화된 미니세포 및 인터페론 감마에 의한 복합 종양 치료
EP3735250A1 (en) Scale up synthesis of silicasome nanocarriers
JP2023533937A5 (OSRAM)
EP3851122A1 (en) Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
JP2021528496A5 (OSRAM)
JP2022507025A5 (OSRAM)
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
JP2018535206A5 (OSRAM)
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
JP2022534724A5 (OSRAM)
CN114469949A (zh) 用于治疗弥漫大b细胞淋巴瘤的喹啉衍生物
US11173173B2 (en) Methods for treating chemoresistant cancer-initiating cells
Praça et al. Current aspects of breast cancer therapy and diagnosis based on a nanocarrier approach
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
US10758526B2 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
RU2021105524A (ru) Способ повышения эффективности противоопухолевого средства
US12611411B2 (en) Triple-agent therapy for cancer treatment
US20150374702A1 (en) Anticancer adjuvant containing pentoxifylline